These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18375654)

  • 21. Regulatory perspectives on data safety monitoring boards: protecting the integrity of data.
    Hemmings R; Day S
    Drug Saf; 2004; 27(1):1-6. PubMed ID: 14720083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. On the independence of data monitoring committee in adaptive design clinical trials.
    Chow SC; Corey R; Lin M
    J Biopharm Stat; 2012; 22(4):853-67. PubMed ID: 22651119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Commentary: preserving confidentiality of interim data.
    Chuang-Stein C; Jiang Q; Marchenko O
    Clin Trials; 2015 Feb; 12(1):18-20. PubMed ID: 25480540
    [No Abstract]   [Full Text] [Related]  

  • 24. Reports to Independent Data Monitoring Committees: An Appeal for Clarity, Completeness, and Comprehensibility.
    Buhr KA; Downs M; Rhorer J; Bechhofer R; Wittes J
    Ther Innov Regul Sci; 2018 Jul; 52(4):459-468. PubMed ID: 29714543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials.
    Fernandes RM; van der Lee JH; Offringa M
    BMC Pediatr; 2009 Dec; 9():77. PubMed ID: 20003383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
    Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
    Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presenting Risks and Benefits: Helping the Data Monitoring Committee Do Its Job.
    Evans SR; Bigelow R; Chuang-Stein C; Ellenberg SS; Gallo P; He W; Jiang Q; Rockhold F
    Ann Intern Med; 2020 Jan; 172(2):119-125. PubMed ID: 31739312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative Framework for Retrospective Assessment of Interim Decisions in Clinical Trials.
    Stanev R
    Med Decis Making; 2016 Nov; 36(8):999-1010. PubMed ID: 27353825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Data monitoring in randomized controlled trials: surveys of recent practice and policies.
    Clemens F; Elbourne D; Darbyshire J; Pocock S;
    Clin Trials; 2005; 2(1):22-33. PubMed ID: 16279576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of the data safety and monitoring board in an international trial.
    NIMH Collaborative HIV/STD Prevention Trial
    AIDS; 2007 Apr; 21 Suppl 2():S99-102. PubMed ID: 17413269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current controversies in data monitoring for clinical trials.
    Pocock SJ
    Clin Trials; 2006; 3(6):513-21. PubMed ID: 17170035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is it ethical to keep interim findings of randomised controlled trials confidential?
    Miller FG; Wendler D
    J Med Ethics; 2008 Mar; 34(3):198-201. PubMed ID: 18316463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stopping clinical trials early for benefit: impact on estimation.
    Freidlin B; Korn EL
    Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A web-based endpoint adjudication system for interim analyses in clinical trials.
    Nolen TL; Dimmick BF; Ostrosky-Zeichner L; Kendrick AS; Sable C; Ngai A; Wallace D
    Clin Trials; 2009 Feb; 6(1):60-6. PubMed ID: 19254936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.
    Korn EL; Freidlin B
    Am J Bioeth; 2011 Mar; 11(3):2-10. PubMed ID: 21400374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials.
    Brosteanu O; Houben P; Ihrig K; Ohmann C; Paulus U; Pfistner B; Schwarz G; Strenge-Hesse A; Zettelmeyer U
    Clin Trials; 2009 Dec; 6(6):585-96. PubMed ID: 19897532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.